Benjamin Pelcman
Scientific Advisor Atrogi
After receiving his Ph.D. in Organic Chemistry at the Royal Institute in Stockholm, and a post doc session at Dartmouth College, USA, Benjamin joined Astra Pain Control as a medicinal chemist. Benjamin later held various positions at Pharmacia & Upjohn, Karo Bio, Biolipox and Orexo. He started a consultancy company, BeePCo, and came in contact with Atrogi, where he eventually was employed as a CEO and later as Head of Chemistry and IP. Benjamin is now retired but is still consulting.
Seminars
Thursday 4th March 2027
The Discovery & Development of ATR-258, a GRK2-Biased β2AR Agonist for the Treatment of Metabolic Disorders
1:30 pm
- Advancing ATR-258 from early discovery into Phase 2 clinical development
- From Type 2 Diabetes and obesity to muscle-preserving weight loss and functional health
- Molecular dynamics calculations reveal a hitherto undescribed β2AR conformation
